
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Indus is the leading global generic drug manufacturer with a strong presence in North America, Europe, Japan, and other key international markets. Their diversified portfolio of both generic and innovative medicines, along with their strong contract manufacturing and distribution services, positions them for continued growth and success. Teva's focus on expanding their biosimilars business through partnerships and their pipeline of promising treatments, such as their TL1A-targeting drug, Duvakitug, is expected to drive multiple expansion and long-term growth. Initiatives to improve their capital structure and mitigate loss of exclusivity risks further support a positive outlook for the company.
Bears say
Teva Pharmaceutical Indus is facing multiple legal and financial challenges, including potential loss of patent protection for its best-selling drug Copaxone, increasing competition in the generic drug market, and ongoing lawsuits and legal battles which may impact its revenue and profitability in the coming years. Additionally, Teva's acquisition of businesses has resulted in significant debt and negative cash flow, putting further strain on the company's financials. Overall, these factors contribute to our negative outlook on Teva's stock.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares